Data for: Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis
The concentration of 1463 proteins were measured using the Olink Explore platform which uses Proximity Extension Assay (PEA) technology. The proteins are preselected from four Olink panels: Explore 384 Cardiometabolic, Explore 384 Inflammation, Explore 384 Neurology, and Explore 384 Oncology. The protein concentrations are given as Olink’s relative protein quantification unit on log2 scale: Normalized Protein Expression (NPX). The NPX values were intensity normalized by Olink. Protein levels were measured in cerebrospinal fluid samples (n = 186) and plasma samples (n = 165) from persons with multiple sclerosis and healthy controls.
Koncentrationen av 1463 proteiner mättes med hjälp av Olink Explore-plattformen som använder Proximity Extension Assay (PEA) teknologi. Proteinerna är förvalda från fyra Olink-paneler: Explore 384 Cardiometabolic, Explore 384 Inflammation, Explore 384 Neurology och Explore 384 Oncology. Proteinernas koncentrationer anges som Olinks relativa proteinmängdsenhet på log2-skalan: Normalized Protein Expression (NPX). NPX-värdena normaliserades (intensity normalization) av Olink. Proteinhalten mättes i ryggvätskeprov (n = 186) och plasmaprov (n = 165) från personer med multipel skleros och friska kontroller.
Proteomics
Proteomik
Multiple sclerosis
Multipel skleros
Landing page for the dataset
Landningssida för datasetet
Linköping University
Linköpings universitet